Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer

The triple-negative breast cancer (TNBC) subtype comprises approximately 15% of all breast cancers and is associated with poor long-term outcomes. Classical chemotherapy remains the standard of treatment, with toxicity and resistance being major limitations. TNBC is a high metabolic group, and antim...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Elena López-Camacho, Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Irene Dapía, Rocío López-Vacas, Andrea Zapater-Moros, María Isabel Lumbreras-Herrera, Pedro Arias, Pilar Zamora, Juan Ángel Fresno Vara, Enrique Espinosa
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2022-05-01
Serie:Biomedicine & Pharmacotherapy
Soggetti:
Triple-negative breast cancer
Antimetabolic drugs
Chemotherapy drugs
Synergism
Accesso online:http://www.sciencedirect.com/science/article/pii/S0753332222002323
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi